Santry Lisa A, McAusland Thomas M, Susta Leonardo, Wood Geoffrey A, Major Pierre P, Petrik Jim J, Bridle Byram W, Wootton Sarah K
Department of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Juravinski Cancer Centre, 699 Concession Street, Hamilton, ON L8V 5C2, Canada.
Mol Ther Methods Clin Dev. 2017 Oct 16;9:181-191. doi: 10.1016/j.omtm.2017.10.004. eCollection 2018 Jun 15.
Newcastle disease virus (NDV) is a single-stranded, negative-sense RNA virus in the family. Although primarily an avian pathogen, NDV is a potent oncolytic virus that has been shown to be safe and effective in a variety of preclinical cancer models and human clinical trials. To produce virus for oncolytic trials, NDV is commonly amplified in embryonated chicken eggs and purified from the allantoic fluid. Conventional methods for purifying virus from allantoic fluid often result in relatively low-titer preparations containing high levels of impurities, including immunogenic chicken host cell proteins from allantoic fluid. However, large quantities of virus need to be delivered intravenously to administer oncolytic NDV systemically to mice. This route of administration requires virus preparations that are both highly concentrated (to enable delivery of small volumes) and highly pure (to limit toxic effects from contaminants). Given the accumulation of promising preclinical and clinical data demonstrating the efficacy of NDV as an oncolytic agent, strategies for increasing the titer and purity of NDV preparations are sorely needed to allow for effective intravenous administration in mice. Here, we describe an optimized protocol for the rescue, production, and purification of high-titer -grade NDV for preclinical studies in mouse models.
新城疫病毒(NDV)是该病毒家族中的一种单链、负链RNA病毒。尽管NDV主要是一种禽类病原体,但它是一种有效的溶瘤病毒,已在多种临床前癌症模型和人体临床试验中显示出安全性和有效性。为了生产用于溶瘤试验的病毒,NDV通常在鸡胚中扩增并从尿囊液中纯化。从尿囊液中纯化病毒的传统方法通常会导致制备的病毒滴度相对较低,且含有高水平的杂质,包括来自尿囊液的具有免疫原性的鸡宿主细胞蛋白。然而,需要静脉注射大量病毒才能将溶瘤性NDV全身给药给小鼠。这种给药途径需要高度浓缩(以便能够注射小体积)且高度纯净(以限制污染物的毒性作用)的病毒制剂。鉴于有大量有前景的临床前和临床数据表明NDV作为溶瘤剂的有效性,迫切需要提高NDV制剂滴度和纯度的策略,以便能在小鼠中进行有效的静脉给药。在此,我们描述了一种优化方案,用于在小鼠模型的临床前研究中拯救、生产和纯化高滴度级别的NDV。